Product introduction:
Pimecrolimus (trade name: aininda) is a macrocyclic lactam derivative of ascomycin. It is a new local non steroidal immunosuppressant. It inhibits T cell activity and the production of various cytokines by inhibiting the activity of calcineurin. Compared with topical glucocorticoid, it has better curative effect and no adverse reaction of skin atrophy. Compared with similar tacrolimus, it has high lipophilicity and stronger affinity with skin. At present, pimecrolimus cream (1%) has been used in a variety of immune and inflammatory skin diseases such as eczema, dermatitis, vitiligo and seborrheic dermatitis. Clinical evidence shows that it has good effects.
CAS:137071-32-0
Molecular formula: C43H68ClNO11
Molecular weight: 810.45
Structural type:
Product purpose:
Pimecrolimus is a local immunomodulator. It is a semi-finished product of ascomycin produced by Streptomyces. It is more lipophilic than tacrolimus and has stronger affinity with the skin. It can effectively and safely control the symptoms and signs of facial seborrheic dermatitis, quickly alleviate the itching symptoms of patients with dermatitis and eczema, reduce the area of skin lesions and remove the signs of specific dermatitis (eczema), It is an effective treatment for early remission and long-term control of specific dermatitis (eczema).